[无可用内容]。

[Not Available].

作者信息

Selle Frédéric, Joly Florence, Gladieff Laurence, Prulhière Karine, Leary Alexandra, Kalbacher Elsa, Rouleau Etienne, Ray-Coquard Isabelle

机构信息

Service d'oncologie médicale, groupe hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France; Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamennais, 75008 Paris, France.

Groupe d'investigateurs nationaux pour les études des cancers de l'ovaire, 8 rue Lamennais, 75008 Paris, France; Département d'oncologie médicale, centre François-Baclesse, 14000 Caen, France.

出版信息

Bull Cancer. 2023 Jun;110(6S):6S5-6S9. doi: 10.1016/S0007-4551(23)00329-6.

DOI:10.1016/S0007-4551(23)00329-6

PMID:37573039

Abstract

Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.

摘要

2023年高级别浆液性和/或子宫内膜样晚期（III-IV期）卵巢癌的管理及HRD-BRCA检测：根据2022年发表/公布的数据更新现在必须对卵巢癌进行系统的分子分析，以确定BRCA1和BRCA2状态以及基因组不稳定评分。有几种类型的检测方法。从临床角度来看，2022年公布的III期临床试验的新数据证实了PARP抑制剂在高级别浆液性卵巢癌一线治疗中的关键作用。提出了一种包含所有新证据的新算法，用于一线治疗的选择。